MSCLF News and Press, Satellos Bioscience Inc. From 11/12/25

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that its leadership team will present and participate in ...

First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and serum biomarkers Results following initial 3 months of treatm...

Adults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment with SAT-3247 Grip strength increased 118.6% and predicted forced vital capacity increased 5.8%; whereas, both decline in natural history SAT-...

2025-10-03 15:44:51 ET More on the markets Should Investors Be Worried About Inflation? The ADP Report Says Layoffs Are Starting, Recession Is Near Macro Insights From September 2025: A Government Shutdown, The Fed's Gamble, And A Bubble Ready To Burst Kalshi...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two scientific posters at the 30th A...

Regulatory submissions filed in the U.S., UK, Europe, Serbia and Australia Three-month randomized placebo-controlled study to assess safety, pharmacokinetics, dose, muscle biopsies, and measures of function in ambulatory children First patient expected to b...

2025-09-02 09:37:25 ET Toronto-based Satellos Bioscience (MSCL.TSX, MSCLF.OTCQB) is a clinical-stage small molecule development company focused on restoring natural muscle repair and regeneration for degenerative muscle diseases. Its proprietary discovery platform, MyoReGenX, identi...

2025-08-13 09:46:55 ET More on Satellos Bioscience Inc. Historical earnings data for Satellos Bioscience Inc. Financial information for Satellos Bioscience Inc. Read the full article on Seeking Alpha For further details see: Satellos Bioscience Inc. GAAP ...

Reported positive Phase 1b data in five adults with Duchenne muscular dystrophy (DMD) after 28 days of treatment Demonstrated safety, tolerability and an approximate doubling in grip strength On track to initiate a follow-up of the Phase 1b study in adults with DMD in ...